Form 4: ORIC CEO Jacob Chacko Reports RSU Vesting and Tax-Related Stock Sale

Oric Pharmaceuticals CEO Jacob Chacko reported the vesting of 83,666 restricted stock units and a subsequent sale of 33,374 shares to cover tax obligations.

Summary

• Jacob Chacko, President and CEO of Oric Pharmaceuticals, Inc. (ORIC), reported transactions involving the company's common stock.
• On December 15, 2025, 83,666 shares of common stock were acquired at a price of $0, resulting from the vesting of restricted stock units (RSUs).
• Following this acquisition, Mr. Chacko's direct beneficial ownership of common stock was 615,085 shares.
• On December 16, 2025, Mr. Chacko disposed of 33,374 shares of common stock at a weighted average price of $9.06 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• After the sale, Mr. Chacko's direct beneficial ownership of common stock decreased to 581,711 shares.
• The RSUs that vested on December 15, 2025, included portions from three separate awards with varying future vesting schedules extending to December 15, 2027.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the vesting of restricted stock units and a subsequent non-discretionary sale to cover tax obligations, which is a common occurrence for executives receiving equity compensation. This is generally neutral, with a slight positive tilt due to the executive's continued equity compensation.

Positives

• The vesting of restricted stock units represents a routine component of executive compensation, indicating continued alignment of management interests with shareholder value.
• The reported sale was non-discretionary, solely for covering tax withholding obligations, rather than a voluntary divestment of shares by the executive.

Negatives

• The sale of 33,374 shares, even for tax purposes, reduces the direct beneficial ownership of common stock by the President and CEO.

Future Outlook

The filing primarily details past transactions related to executive compensation and does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the scheduled future vesting dates for certain RSU awards.

Management Comments

• The sale of 33,374 shares represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all industries, particularly for executives receiving equity-based compensation. It reflects standard compensation practices within the biotechnology and pharmaceutical sectors, where stock options and restricted stock units are frequently used to align executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect standard executive compensation practices. The non-discretionary nature of the sale mitigates concerns about management's confidence in the company's future. The executive continues to hold a significant number of shares, maintaining alignment with shareholder interests.

Next Steps

• Future vesting of remaining Restricted Stock Units on December 15, 2026, and December 15, 2027, as per the original award schedules.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation, specifically the vesting of restricted stock units and a subsequent non-discretionary sale to cover tax obligations. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not provide new information that would warrant a change in investment recommendation.

Keywords

Oric Pharmaceuticals, ORIC, Jacob Chacko, SEC Form 4, Insider Transaction, RSU Vesting, Stock Sale, Tax Withholding, Beneficial Ownership